Finance & Capital Markets

  1. Origins Of A Biopharma VC Deal With Bernat Olle, Ph.D. And Parag Shah 6/21/2023

    Here's a behind-the-scenes breakdown of how Vedanta Biosciences secured the support of K2 Health Ventures in its recent $100 million+ financing to fund a pivotal Phase 3 study.

  2. BoB@JPM: Nima Farzan, Latigo Biotherapeutics 3/19/2025

    In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission.

  3. Picking Biotech Jockeys With SR One's Simeon George, M.D. 9/15/2024

    SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. On the Business of Biotech, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. Listen now!

  4. The Innovation Reduction Act With Allan Shaw 5/31/2023

    Allan Shaw posits that the Inflation Reduction Act (IRA) will stifle momentum in the biopharma industry and suggests its impact will ultimately cost patients and payers more. Tune in to learn why.

  5. Building Flagship Pioneering With Avak Kahvejian, Ph.D. 4/26/2023

    Flagship Pioneering is fertile ground for a bevy of blossoming biotechs, and one of its most prolific sowers is General Partner Avak Kahvejian, Ph.D. Dr. Kahvejian counts Seres Therapeutics, Rubius Therapeutics, Codiak BioSciences, Cygnal Therapeutics, Ring Therapeutics, Cellarity, Laronde, and Generate Biomedicines among the companies he's played a leading hand in launching. On this episode of the Business of Biotech, Kahvejian takes us under the hood of one of the most burgeoning businesses in biotech, sharing details on the people, processes, and technologies fueling its rapid growth.

  6. Strategic Deals With CinRx's Gavin Samuels, M.D. 3/17/2024

    Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.

  7. A New Prescription For PBMs with Allan Shaw 5/12/2024

    Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab.

  8. Biotech Is Back With Allan Shaw 1/24/2024

    The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and we're kicking things off with everyone's favorite life sciences CFO, Allan Shaw.

  9. Biotech Cash Management With Allan Shaw 8/2/2023

    It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

  10. Managing Mergers With Sail's Guillaume Pfefer, Ph.D 2/15/2024

    You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.